BEC2 ANTI - IDIOTYPIC MONOCLONAL ANTIBODY Sample Clauses

BEC2 ANTI - IDIOTYPIC MONOCLONAL ANTIBODY. The GD3 ganglioside is reported to be distributed in various tumor cell lines in amounts ranging from 0 percent (colon carcinoma) to 100 percent (metastatic melanoma and small cell lung cancer) (Fuenxxx 0007, Hougxxxx personal communication). An IgG3 monoclonal antibody, R24, which recognizes the human melanoma GD3 ganglioside was raised in syngenic [(C57BL X BALB/c)F1] mice. Additional syngenic mice were immunized with the R24 monoclonal antibody which resulted in the formation of two anti-idiotypic monoclonal antibodies, designated BEC2 and BEC3 (Chapxxx 1991). Both were screened for antibody production in New Zealand white rabbits, which express the GD3 ganglioside on normal tissue (brain, adrenal, thymus, spleen, small bowel) in distributions similar to that seen in humans (Iwamori 1978, 1981; Sekine 1985). Both BEC2 and BEC3 induced anti-mouse and anti-R24 antibodies, but only BEC2 induced anti-GD3 antibodies (Chapxxx 0001). No toxicity's were observed in the rabbits immunized with BEC2 and necropsy results showed no evidence of inflammation within tissues known to express GD3. 11/102 29 [LOGO] The SILVX xxxdy -------------------------------------------------------------------------------- Numerous publications have reported increased immunogenicity, desired serological responses, and mild toxicity's of anti-id MAb in combination with adjuvants (Mittxxxxx 0000, 1992), aluminum salts (Glenny 1926) or aluminum hydroxide-adsorbed vaccine preparations (Aprixxx 0006). Vaccination with BEC2, a murine anti-idiotvpic monoclonal antibody, could evoke specific IgM and IgG against GD3 in animal models (Chapxxx xxx Houghton, 1991). Based on these reports. ImClone Systems Inc., NY, NY sponsored and conducted phase Ib/IIa studies with BEC2 alone and in combination with various adjuvants.
AutoNDA by SimpleDocs

Related to BEC2 ANTI - IDIOTYPIC MONOCLONAL ANTIBODY

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Product The term “

  • Know-How The term “

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

Time is Money Join Law Insider Premium to draft better contracts faster.